DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway
Open Access
- 8 August 2022
- journal article
- retracted article
- Published by Hindawi Limited in Disease Markers
- Vol. 2022, 1-11
Abstract
In prior research, 6,12-diphenyl-3,9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate (DDTC) has been shown to be an effective inhibitor of the growth of the SKOV3 and A2780 ovarian cancer (OC) cell lines. Flow cytometry analyses indicated that DDTC was able to suppress P-CNA expression at the protein level within OC cells, while RNA-seq indicated that DDTC treatment was associated with marked changes in gene expression profiles within A2780 cells. Molecular docking analyses suggested that DDTC has the potential to readily dock with key signaling proteins including PI3K, AKT, and mTOR. In line with these findings, DDTC treatment inhibited the growth of xenograft tumors in a mouse model system. Such treatment was also associated with reduced p-PI3K/PI3K, p-AKT/AKT, p-mTOR/mTOR, and CyclinD1 (CCND1) expressions and with the increased expression of PTEN in vitro and in vivo. Together, these results suggest that DDTC is capable of readily inhibiting OC development at least in part via targeting and modulating signaling via the PI3K/AKT/mTOR axis.Keywords
Funding Information
- Program of Scientific Research Foundation in Universities of Hebei Province (QN2021109, 15967730D)
This publication has 18 references indexed in Scilit:
- Determination of long non-coding RNAs associated with EZH2 in neuroblastoma by RIP-seq, RNA-seq and ChIP-seqOncology Letters, 2020
- 6,12-Diphenyl-3, 9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate Inhibits Proliferation, Migration and Promotes Apoptosis in Ovarian Cancer CellsDisease Markers, 2020
- Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancerCancer Treatment Reviews, 2020
- Targeting AKT for cancer therapyExpert Opinion on Investigational Drugs, 2019
- Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor LesionsClinical Cancer Research, 2018
- Melatonin as a promising agent to treat ovarian cancer: molecular mechanismsCarcinogenesis, 2017
- The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancerGynecologic Oncology, 2015
- Photodimerization of 4-Aryl-1,4-dihydropyridines in 1-Butyl-3-methylimidazolium TetrafluoroborateChemistry Letters, 2014
- An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceJournal of Clinical Investigation, 2012
- Cage Dimeric 4-Aryl-1,4-dihydropyridines as Promising Lead Structures for the Development of a Novel Class of HIV-1 Protease InhibitorsArchiv der Pharmazie, 1999